Ling, Susan
Ceban, Felicia
Lui, Leanna M. W.
Lee, Yena
Teopiz, Kayla M.
Rodrigues, Nelson B.
Lipsitz, Orly
Gill, Hartej
Subramaniapillai, Mehala
Mansur, Rodrigo B.
Lin, Kangguang
Ho, Roger
Rosenblat, Joshua D.
Castle, David
McIntyre, Roger S.
Article History
Accepted: 28 October 2021
First Online: 17 November 2021
Declarations
:
: This paper was not funded.
: Dr. Roger McIntyre has received research grant support from CIHR/GACD/Chinese National Natural Research Foundation; speaker/consultation fees from Lundbeck, Janssen, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Abbvie. Dr. Roger McIntyre is a CEO of Braxia Scientific Corp. Dr. Joshua D. Rosenblat is the medical director of the Braxia Health (formally known as the Canadian Rapid Treatment Center of Excellence and is a fully owned subsidiary of Braxia Scientific Corp) which provides ketamine and esketamine treatment for depression; he has received research grant support from the American Psychiatric Association, the American Society of Psychopharmacology, the Canadian Cancer Society, the Canadian Psychiatric Association, the Joseph M. West Family Memorial Fund, the Timeposters Fellowship, the University Health Network Centre for Mental Health, and the University of Toronto and speaking, consultation, or research fees from Allergan, COMPASS, Janssen, Lundbeck, and Sunovion. Dr. Yena Lee is an employee of Braxia Scientific Corp. Leanna M.W. Lui has received: personal fees from Braxia Scientific Corp and honoraria Medscape. Kayla M. Teopiz has received personal fees from Braxia Scientific Corp. All other authors declare no conflicts of interest and/or financial disclosures.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: SL, FC, and RSM drafted the manuscript. All authors provided critical feedback and revisions, approved the final manuscript, and agreed to be accountable for the work.